News >

Findings Support Early Use of CD19 CAR T-Cell Therapy in Relapsed B-cell ALL

By Gina Columbus
Published: Friday, Apr 21, 2017

Jae Park, M

Jae Park, MD

Low disease burden prior to treatment with CD19-specific chimeric antigen receptor (CAR) T-cell therapy appears to be a positive prognostic factor for long-term survival outcomes of patients with relapsed B-cell acute lymphoblastic leukemia (ALL), according to retrospective results of a phase I trial. Additionally, the use of allogeneic stem cell transplant posttreatment did not appear to have an effect. The authors concluded that these findings support early use of CD19 CAR T-cell therapy prior to morphologic relapse in patients with B-cell ALL.

= .0001, respectively), the authors noted. Five percent and 15% of patients in the MRD cohort experienced CRS and neurotoxicity, respectively, while the adverse events occurred in 42% and 58% of the morphologic patients. There were no reports of cerebral edema in either cohort.
Park JH, Rivere I, Wang X, et al. Impact of disease burden and transplant on long-term survival after CD19 CAR therapy in adults with relapsed B-cell acute lymphoblastic leukemia. In: Proceedings from the 2017 AACR Annual Meeting; April 1-5, 2017; Washington, DC. Abstract CT078.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Advances in™ Multiple Myeloma: Changing Treatment Paradigms and the Emerging Potential of CAR T-Cell TherapyAug 30, 20191.5
2nd Annual Live Medical Crossfire®: Hematologic Malignancies OnlineSep 28, 20198.0
Publication Bottom Border
Border Publication